One-glance verdict
Within fair range
$102.92 our estimate vs market $157.00
Wall Street consensus: $147.53 (43.3% higher than our fair-value estimate)
53% above our estimate
Fundamentals snapshot
Revvity, Inc.
RVTY · NYQ · Healthcare · Diagnostics & Research
Current price
$157.00
52-week range
$81.22 - $169.06
Market cap
$17.52B
Balance sheet
Stretched
3.87x Stretched
Net debt $2.32B. Interest coverage shows how many times profit covers the interest bill.
What stands out
3 Rewards
3 Risks
3 rewards · 3 risks
- Reward Revenue grew 2.0% last year.
- Reward Returns 3.2% on equity, ahead of 50% of its peers.
- Risk Stock trades 103.3% above its 5-year average P/E.
- Risk Operating margin compressed from 22.4% to 17.1% over 3 years.
What this company does
Revvity, Inc.
Revvity provides tools and services to healthcare and life science researchers, mainly selling diagnostic tests and genetic analysis technologies. Their money primarily comes from selling these instruments, chemicals (reagents), and specialized software used for detecting diseases and understanding genetics. This matters because it helps doctors and scientists diagnose illnesses earlier and develop new treatments.
How the company got here
Revvity began as a long-standing company called PerkinElmer, founded in 1937. Over many years, it grew by acquiring other companies, shifting its focus more towards healthcare and life sciences. A major turning point came in 2023 when it sold off its applied, food, and enterprise services businesses to become a more focused health sciences company. After this sale, the remaining life sciences and diagnostics businesses were rebranded as Revvity, a name combining "revolutionize" and "vita" (Latin for life).
What it actually does
Revvity provides the tools, technologies, and services that scientists and doctors use to research, diagnose, and develop treatments for diseases. Think of them as a crucial supplier for pharmaceutical and biotech companies, diagnostic labs, and research universities. Their products range from scientific instruments and software to the specific chemical mixtures (reagents) needed to run tests. For example, they provide the technology used in newborn screening for rare diseases, infectious disease testing, and in the discovery of new drugs.
Life Sciences
This is one of the two main parts of Revvity's business. It provides instruments, software, and critical supplies (reagents and antibodies) to researchers in pharmaceutical companies, universities, and government labs. These customers use Revvity's products to discover and develop new drugs and therapies. This segment focuses on providing complete workflows, meaning they offer a combination of tools and materials that scientists need to perform complex analyses, like studying cells and genes.
Diagnostics
The other major part of the company focuses on tools for clinical decision-making. This segment provides instruments, test kits, and software to clinical laboratories for things like screening newborns for diseases, reproductive health testing, and identifying autoimmune and infectious diseases. For instance, hospitals and public health authorities use their products to test for genetic abnormalities and other health conditions. This business is important because once a lab uses a Revvity instrument, they often continue to buy the specific tests and supplies that run on it, creating a recurring source of revenue (income that is likely to continue in the future).
What management is betting on now
Management's strategy is to be a more focused health sciences company, moving away from just selling one-time equipment. They are emphasizing businesses that generate recurring revenue, such as selling the consumable supplies (reagents and assay kits) that customers need to buy repeatedly to use the instruments they've already purchased. The company is also concentrating on high-growth areas like reproductive health, newborn screening, and immunology. A key goal is to provide complete workflows that combine instruments, software, and supplies to become a more essential partner to their research and clinical customers.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$149.78M
FY2025 Q1
$112.17M
FY2025 Q2
$115.45M
FY2025 Q3
$120.00M
FY2025 Q4
$161.79M
FY2026 Q2
$95.45M
FY2026 Q3
$180.87M
Revenue
$729.69M
Net income
$51.82M
Diluted EPS
0.47
Operating cash flow
$191.94M
Free cash flow
$180.87M
Fetching…
Sources
Revenue
$711.12M
Net income
$40.72M
Diluted EPS
0.36
Operating cash flow
$115.23M
Free cash flow
$95.45M
Fetching…
Sources
Revenue
$772.06M
Net income
$98.36M
Diluted EPS
0.86
Operating cash flow
$181.96M
Free cash flow
$161.79M
Fetching…
Sources
Revenue
$698.95M
Net income
$46.65M
Diluted EPS
0.40
Operating cash flow
$138.50M
Free cash flow
$120.00M
Fetching…
Sources
Revenue
$720.28M
Net income
$53.95M
Diluted EPS
0.46
Operating cash flow
$134.32M
Free cash flow
$115.45M
Fetching…
Sources
Revenue
$664.76M
Net income
$42.24M
Diluted EPS
0.35
Operating cash flow
$128.16M
Free cash flow
$112.17M
Fetching…
Sources
Revenue
$729.37M
Net income
$94.64M
Diluted EPS
0.77
Operating cash flow
$174.23M
Free cash flow
$149.78M
Fetching…
Sources
Is it cheap or expensive?
Fair value $102.92 vs current price $157.00
Wall Street consensus is the average analyst price target: $147.53 (43.3% higher than our fair-value estimate).
Our most-likely fair value is $102.92 a share — about 34.4% away from today's price of $157.00, so the stock currently looks fairly priced.
Is it drowning in debt?
Stretched
Net debt $2.3B. Interest coverage 3.9x.
Net debt
$2.32B
Interest coverage
3.87x
Revvity, Inc.'s profit covers its interest bill about 3.9 times over. which is weaker than most peers shown here.
Stretched
Worse cushion
Baseline
Better cushion
RVTY
BASELINE
Revvity, Inc.
Total debt $3.34B Interest coverage 3.87x This is the baseline the peer rows are being compared against.
Total debt $289.09M Interest coverage 28.31x +632% vs RVTY Carries about 7.3x more debt cushion than RVTY.
Total debt $1.86B Interest coverage 3.91x +1% vs RVTY Has roughly the same debt cushion as RVTY.
Total debt $1.37B Interest coverage 4.46x +15% vs RVTY Carries about 1.2x more debt cushion than RVTY.
Total debt $1.65B Interest coverage 15.65x +304% vs RVTY Carries about 4.0x more debt cushion than RVTY.
Total debt $5.48B Interest coverage 11.54x +198% vs RVTY Carries about 3.0x more debt cushion than RVTY.
What you should know
The case for and against RVTY
3 Rewards
3 Risks
Rewards
-
Revenue grew 2.0% last year.
-
Returns 3.2% on equity, ahead of 50% of its peers.
-
Free cash flow was positive in 10/10 years.
Risks
-
Stock trades 103.3% above its 5-year average P/E.
-
Operating margin compressed from 22.4% to 17.1% over 3 years.
-
Insider ownership is only 0.3% (peer median: 0.5%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
75.12x
Forward P/E
26.64x
P/B
2.42x
P/S
6.02x
EV/EBITDA
22.65x
PEG ratio
0.73x
Profitability
How much profit each dollar creates
Gross margin
55.0%
Operating margin
17.1%
Net margin
8.2%
ROE
3.2%
ROA
2.4%
Health
Liquidity and balance-sheet strength
Debt / equity
0.46x
Current ratio
1.80x
Quick ratio
1.36x
Total debt
$3.34B
Total cash
$1.02B
Growth
How the business has been compounding
Revenue TTM
$2.91B
Revenue 5Y CAGR
-13.4%
EPS TTM
2.09
EPS 5Y CAGR
-23.3%
Cash flow
How much cash the business throws off
Operating CF TTM
$627.63M
Free CF TTM
$509.41M
FCF margin
17.5%
Dividend
Shareholder payout
Yield
0.2%
Payout ratio
13.4%
Last ex-div date
2026-10-23